Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post‐transplant EBV‐associated autoimmune hemolytic anemia
- 10 November 2005
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 75 (6) , 527-529
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Persistent Panhypogammaglobulinemia After CHOP-Rituximab for HIV-Related LymphomaJournal of Clinical Oncology, 2005
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaBlood, 2004
- Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein–Barr virus-associated lymphoproliferative diseaseBone Marrow Transplantation, 2003
- Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patientAnnals of Hematology, 2003
- Common Variable Immunodeficiency Patient Classification Based on Impaired B Cell Memory Differentiation Correlates with Clinical AspectsJournal of Clinical Immunology, 2003
- Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphomaBritish Journal of Haematology, 2003
- TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMABTransplantation, 2002
- Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failureBone Marrow Transplantation, 2001
- CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantationBlood, 2000
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997